New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 47, Issue 3, Pages 687-694
Publisher
Springer Science and Business Media LLC
Online
2020-01-04
DOI
10.1007/s00259-019-04674-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT
- (2019) Maurits Wondergem et al. CLINICAL NUCLEAR MEDICINE
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- (2019) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004–2014
- (2018) Jun Li et al. ANNALS OF EPIDEMIOLOGY
- Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells
- (2018) Benedikt Kranzbühler et al. PROSTATE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
- (2018) Yong Joong Kim et al. CLINICAL NUCLEAR MEDICINE
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- PSMA Ligands for PET Imaging of Prostate Cancer
- (2017) Sarah M. Schwarzenboeck et al. JOURNAL OF NUCLEAR MEDICINE
- 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
- (2017) Wolfgang P. Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
- (2016) Madhav Prasad Yadav et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68 Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
- (2016) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- (2016) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
- (2016) Wolfgang P. Fendler et al. Oncotarget
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy
- (2015) B. Meller et al. EJNMMI Research
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Semi-Automated Technique Determining the Liver Standardized Uptake Value Reference for Tumor Delineation in FDG PET-CT
- (2014) Kenji Hirata et al. PLoS One
- Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer
- (2014) Jose D. Murga et al. PROSTATE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterising the castration-resistant prostate cancer population: a systematic review
- (2011) M. Kirby et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
- (2008) Andrea Schaefer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started